<DOC>
	<DOCNO>NCT01170663</DOCNO>
	<brief_summary>This Phase III randomize multicenter double-blind , placebo control trial evaluate safety efficacy paclitaxel plus ramucirumab ( IMC-1211B ) drug product ( DP ) compare paclitaxel plus placebo .</brief_summary>
	<brief_title>A Study Paclitaxel With Without Ramucirumab ( IMC-1211B ) Metastatic Gastric Adenocarcinoma</brief_title>
	<detailed_description>The aim study determine paclitaxel give together ramucirumab ( IMC-1211B ) second line therapy prolong overall survival ( OS ) compare paclitaxel alone . Approximately 663 participant ( least 18 year ) approximately 200 study center approximately 30 country randomize histologically cytologically confirm metastatic gastric gastroesophageal junction adenocarcinoma . Participants must receive least one cycle first line therapy platinum/fluoropyrimidine doublet without anthracycline ( epirubicin doxorubicin ) must discontinue therapy prior study entry due disease progression . Upon registration completion screen procedure review Inclusion Exclusion Criteria eligible participant randomize receive either paclitaxel plus ramucirumab paclitaxel plus placebo . Ramucirumab ( IMC-1211B ) DP/placebo administer IV Days 1 15 , paclitaxel administer IV Days 1 , 8 15 4 weekly cycle . Participants continuously treat monitored radiographic symptomatic progression disease , toxicity require cessation , protocol noncompliance , withdrawal consent .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Signed informed consent histologically cytologically confirm gastric gastroesophageal junction adenocarcinoma Metastatic disease locally advance , unresectable disease Disease progression within 4 month last dose firstline therapy ( platinum/fluoropyrimidine doublet without anthracycline ) Organs function well ( liver , kidney , blood ) Good performance status Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 First line chemotherapy metastatic gastric cancer platinum/fluoropyrimidine doublet without anthracycline Previous systemic therapy antiangiogenic drug Uncontrolled high blood pressure Symptomatic poorly control heart disease heart attack stroke within last 6 month Evidence central nervous system ( CNS ) metastasis baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metastatic Adenocarcinoma</keyword>
	<keyword>Gastric Adenocarcinoma</keyword>
	<keyword>Gastroesophageal Junction Adenocarcinoma</keyword>
</DOC>